ATE439836T1 - Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel - Google Patents

Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Info

Publication number
ATE439836T1
ATE439836T1 AT04767442T AT04767442T ATE439836T1 AT E439836 T1 ATE439836 T1 AT E439836T1 AT 04767442 T AT04767442 T AT 04767442T AT 04767442 T AT04767442 T AT 04767442T AT E439836 T1 ATE439836 T1 AT E439836T1
Authority
AT
Austria
Prior art keywords
composition containing
anticancer agent
phosphatase inhibitor
cdc25 phosphatase
cdc25
Prior art date
Application number
AT04767442T
Other languages
German (de)
English (en)
Inventor
Gregoire Prevost
Pannetier Marie-Christine Brezak
Christian Diolez
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE439836T1 publication Critical patent/ATE439836T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04767442T 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel ATE439836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
ATE439836T1 true ATE439836T1 (de) 2009-09-15

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04767442T ATE439836T1 (de) 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel

Country Status (14)

Country Link
US (3) US20060281736A1 (https=)
EP (3) EP1792905A1 (https=)
JP (2) JP2007514639A (https=)
AR (2) AR044930A1 (https=)
AT (1) ATE439836T1 (https=)
CA (1) CA2530668A1 (https=)
DE (1) DE602004022674D1 (https=)
DK (1) DK1641453T3 (https=)
ES (1) ES2332137T3 (https=)
FR (1) FR2856688B1 (https=)
MX (1) MXPA06000216A (https=)
MY (1) MY141725A (https=)
PL (1) PL1641453T3 (https=)
WO (1) WO2005000852A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2190924B1 (de) * 2007-09-06 2011-05-25 Basf Se Blends aus verzweigten polyarylethern und hydrophilen polymeren
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI421252B (zh) 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
JP2023503318A (ja) 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
EP1233787B8 (fr) * 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
EP1345941A1 (fr) * 2000-12-20 2003-09-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
US20090253685A1 (en) 2009-10-08
WO2005000852A2 (fr) 2005-01-06
US20060281736A1 (en) 2006-12-14
EP1641453A2 (fr) 2006-04-05
AR044930A1 (es) 2005-10-12
US20090137596A1 (en) 2009-05-28
AR070977A2 (es) 2010-05-19
FR2856688A1 (fr) 2004-12-31
EP1641453B1 (fr) 2009-08-19
DK1641453T3 (da) 2009-12-14
FR2856688B1 (fr) 2008-05-30
WO2005000852A3 (fr) 2005-06-30
EP1792905A1 (fr) 2007-06-06
MY141725A (en) 2010-06-15
ES2332137T3 (es) 2010-01-27
JP2009149694A (ja) 2009-07-09
PL1641453T3 (pl) 2010-01-29
EP2335702A1 (fr) 2011-06-22
DE602004022674D1 (de) 2009-10-01
MXPA06000216A (es) 2006-04-11
JP2007514639A (ja) 2007-06-07
CA2530668A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
ATE439836T1 (de) Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel
ATE466855T1 (de) Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
EP1587482A4 (en) INFLAMMATORY COMPOSITIONS AND ITS USES
EP1781098A4 (en) ANTIMICROBIAL DEVICES AND COMPOSITIONS THEREFOR
ATE361053T1 (de) Kits für die mundpflege und zusammensetzungen
EP1552814A4 (en) FRAGRANCE COMPOSITION
PL2277976T3 (pl) Kompozycje zawierające HFC-1234ZE i smar
ATE515495T1 (de) Gamma sekretase inhibitoren
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
IL174128A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL217315A0 (en) Tetracycline derivatives and compositions comprising the same
MX2008006586A (es) Composicion edulcorante de alta potencia con un agente antiinflamatorio y composiciones edulcoradas con la misma
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
EP1680535A4 (en) METHODS AND COMPOSITIONS FOR GALVANOPLASTY
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL187997A0 (en) Indane derivatives and pharmaceutical compositions containing the same
EP1512408A4 (en) ANTIBACTERIAL AGENT AND ANTIBACTERIAL COMPOSITION
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
ATE539138T1 (de) Schmierstoffzusammensetzungen
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
ATE352301T1 (de) Antineoplastische zusammensetzungen
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE60232673D1 (de) Zusammensetzungen, die combretastatin und krebsbekämpfendes mittel enthalten
EP1925319A4 (en) SC (FV) 2 PHARMACEUTICAL COMPOSITIONS CONTAINING

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties